Public Research Library
Specialties:
Most Popular Reports:
- Laser Body Sculpting SmartLipo-Trends in Use
- Essure Permanent Birth Control
- Oral Contraceptives Market Evaluation
- Trends and Forecast of Dental Implant Cases
- Avastin and the AVADO Trial Survey
Newest Reports:
Revlimid in the
A Survey of 50 Hematology/Oncology Specialists
January 2008
Deliverable: Survey with key findings.
Study Description:
|
Topic |
Revlimid in the U.S. Multiple Myeloma Market |
|
Respondent Type |
Physicians |
|
Specialties Covered |
Hematology/Oncology Specialists |
|
Region |
United States Only |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: Approximately 30 minutes’ duration Size: 50 total respondents Fielding Dates: Fielded online from December 24, 2007 to December 28, 2007 |
Objectives:
To understand current practices and trends regarding the use of newly approved agents in patients with multiple myeloma (MM).
§ Determine current practice patterns in MM.
§ Quantify usage of newly indicated agents in MM patients.
§ Gain understanding of recent data presented at the 2007 American Society of Hematology conference.
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Celgene Corporation |
CELG |
Revlimid & Thalomid |
|
Millennium |
MLNM |
Velcade |
Inclusion Criteria and Respondent Demographics:
|
Inclusion Criteria
|
§ 50 Hematology/Oncology specialists § At least 2 years in practice post-training § Spend at least 75% time in patient care § Manage at least 25 multiple myeloma patients § Have at most 75% of MM patients enrolled in clinical trials |
Reports become free one year after the publication date.
 about us contact us |
 |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |